Abstract
Transplantation of insulin-producing cells offers a promising therapy to treat diabetes. However, due to the limited number of donor islet cells available, researchers are looking for different sources of pancreatic islet progenitor or stem cells. A stem cell with extensive proliferative ability may provide a valuable source of islet progenitor cells. Several studies have demonstrated that a progenitor/stem-cell population can be expanded in vitro to generate large numbers of islet progenitor cells. However, efficient and directed differentiation of these cells to an endocrine pancreatic lineage has been difficult to achieve. We discuss here various pancreatic islet stem cells that we and others have obtained from embryonic, fetal or adult human tissues. We review the progress that has been achieved with pancreatic islet progenitor cell differentiation in the last 2 decades and discuss how close we are to translate this research to the clinics.
Keywords: hESC differentiation, Nestin positive cells, fetal pancreas, Transplantation, multipotent adult progenitor cells
Current Stem Cell Research & Therapy
Title: Stem-Cell Therapy for Diabetes Cure: How Close are We?
Volume: 1 Issue: 3
Author(s): Anandwardhan A. Hardikar, Justin G. Lees, Kuldip S. Sidhu, Emily Colvin and Bernard E. Tuch
Affiliation:
Keywords: hESC differentiation, Nestin positive cells, fetal pancreas, Transplantation, multipotent adult progenitor cells
Abstract: Transplantation of insulin-producing cells offers a promising therapy to treat diabetes. However, due to the limited number of donor islet cells available, researchers are looking for different sources of pancreatic islet progenitor or stem cells. A stem cell with extensive proliferative ability may provide a valuable source of islet progenitor cells. Several studies have demonstrated that a progenitor/stem-cell population can be expanded in vitro to generate large numbers of islet progenitor cells. However, efficient and directed differentiation of these cells to an endocrine pancreatic lineage has been difficult to achieve. We discuss here various pancreatic islet stem cells that we and others have obtained from embryonic, fetal or adult human tissues. We review the progress that has been achieved with pancreatic islet progenitor cell differentiation in the last 2 decades and discuss how close we are to translate this research to the clinics.
Export Options
About this article
Cite this article as:
Hardikar A. Anandwardhan, Lees G. Justin, Sidhu S. Kuldip, Colvin Emily and Tuch E. Bernard, Stem-Cell Therapy for Diabetes Cure: How Close are We?, Current Stem Cell Research & Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157488806778226830
DOI https://dx.doi.org/10.2174/157488806778226830 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Method of Inhibition of Activity of Tumor Necrosis Factor Alpha In Patients with Psoriasis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Skeletal Muscle in Motor Neuron Diseases: Therapeutic Target and Delivery Route for Potential Treatments
Current Drug Targets Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Epidemiological Characteristics and Risk Factors of Tinea Pedis Disease Among Adults Attending Tikrit Teaching Hospital/ Iraq
Infectious Disorders - Drug Targets Hospital Management of Severe Hypertriglyceridemia in Children
Current Pediatric Reviews Meet Our Editorial Board Member:
Current Aging Science Pharmaceutical Nanotechnology United States Patent Watch (October – December 2014)
Pharmaceutical Nanotechnology Long-lasting Insulin Treatment Via a Single Subcutaneous Administration of Liposomes in Thermoreversible Pluronic® F127 Based Hydrogel
Current Pharmaceutical Design Recent Advances in Immune Modulation
Current Gene Therapy Autoimmune Neuromuscular Disorders
Current Neuropharmacology Cardiosphere-derived Progenitor Cells for Myocardial Repair Following Myocardial Infarction
Current Pharmaceutical Design Chips for Brains
Current Genomics Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Biochemical Markers and Risk Factors of Alzheimers Disease
Current Alzheimer Research Editorial (Hot Topic:Sirtuins as Drug Targets)
Current Drug Targets CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study)
Current Diabetes Reviews Nicotinic Acid Regulates Glucose and Lipid Metabolism Through Lipidindependent Pathways
Current Pharmaceutical Biotechnology Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design Arterial Stiffness and Cardiovascular Drugs
Current Pharmaceutical Design